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ntroduction: The tolerability of lamotrigine as adjunctive and monotherapy in
atients requiring a change in antiepileptic drug (AED) therapy was assessed in this
ulticenter, open-label study. Open-label studies conducted in the clinic setting may
rovide additional drug tolerability and effectiveness information that may not be
vident in pre-approval clinical trials.
ethods: Adult patients with partial seizures received adjunctive lamotrigine for 16
eeks. Patients taking a single enzyme-inducing AED could convert to lamotrigine
onotherapy for an additional 12 weeks. Patients were assessed at baseline, end of
djunctive therapy, and end of monotherapy using the Liverpool Adverse Experience
rofile (AEP), Quality of Life in Epilepsy-31, a patient satisfaction rating, and a
ubjective investigator global assessment.
esults: Of the 547 patients enrolled (mean age 42.7 years, 58% female), 421 (77%)
ompleted adjunctive therapy. Upon completion of the adjunctive phase, mean
mprovement from baseline was 4.3 points on the AEP, and investigators rated 71%
f patients as improved in global status. Overall score on the QOLIE 31 improved by 10
oints from baseline. One hundred and seventy-eight patients entered and 143 (80%)
atients completed the monotherapy phase. In patients completing lamotrigine
onotherapy, mean improvement from baseline was 5.9 points on the AEP, and
nvestigators rated 92% as improved in global status. Overall score on the QOLIE
1 score improved by 15 points from baseline.pilepsy Society Annual Meeting 2002, Seattle, WA.
83 6925.
m (R.P. Kustra).
5 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
Lamotrigine adjunctive and monotherapy 255Conclusion: Lamotrigine as adjunctive treatment and monotherapy may imp-
rove side effect burden and quality of life in patients requiring a change in AED
therapy.
# 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
This study was a large, multicenter, open-label
investigation of adults with partial seizures who
required a change in their current AED regimen
because of inadequate seizure control, unaccep-
table side effects, or both. Open-label studies
conducted in the clinic setting may provide addi-
tional drug tolerability and effectiveness informa-
tion that may not be evident in pre-approval
clinical trials. Because of restrictive inclusion
and exclusion criteria, treatment groups in clinical
trials for regulatory approval may not be repre-
sentative of the population treated once a drug
comes into general use. These trials, for various
reasons, often do not accurately reflect the effec-
tiveness of AEDs when used in the clinic setting.
Despite their shortcomings, the value of large,
open-label clinical studies includes an opportunity
to document aspects of clinical response, including
quality of life and safety issues that may be evident
in the more routine use of the AED yet not apparent
in more rigorous registration-based trials. Results
from similarly designed studies with gabapentin
and levetiracetam have been recently pub-
lished.1,2
Lamotrigine [Lamictal1; 6-(2,3—dichlorophe-
nyl)—1,2,4 triazine—3,5 diamine] is chemically
unrelated to other currently marketed AEDs. The
anticonvulsant effects of lamotrigine may result
from its ability to block presynaptic voltage sensi-
tive sodium channels, thereby stabilizing neuronal
membranes and inhibiting the release of excitatory
amino acid neurotransmitters (e.g. glutamate and
aspartate) that play a role in the generation and
spread of epileptic seizures.3 An additional rece-
ntly described mechanism involves regulation of
the inward hyperpolarization current (Ih).4,5 Ele-
ven double-blind, placebo-controlled studies have
demonstrated that lamotrigine is effective and
well-tolerated when added to current antiepilep-
tic therapy.6 Lamotrigine has been shown to be
safe and effective in double-blind trials for con-
version to monotherapy7 and for initial monother-
apy.8,9 However, the benefits of converting to
lamotrigine monotherapy in terms of side effect
reduction and quality of life improvement in a
general clinical practice setting have not been
reported.Methods
Investigator selection
Investigators were predominantly community neu-
rologists with active epilepsy practices in the United
States.
Patient selection
Patients aged 16 years and above were considered
for entry into the study if they had a confident
diagnosis of epilepsy with partial seizures (simple
or complex, with or without secondary generaliza-
tion) and were taking one or two AEDs of any type.
These patients required a change in therapy
because of inadequate seizure control, unaccepta-
ble side effects, or both. Patients were required to
be capable of completing seizure diaries and self-
rated questionnaires.
Patients were not eligible to participate in the
study if they had received lamotrigine within 30
days prior to enrollment; had a history of known
or suspected hypersensitivity to lamotrigine or a
history of nonepileptic seizures; were currently
undergoing vagal nerve stimulation or planning sur-
gery to control seizures during the study; were
currently participating in another clinical trial or
planning to enroll in another trial while participat-
ing in this trial; were pregnant or lactating; had a
presence of severe hepatic or renal insufficiency,
severe hematologic disease, or a clinically signifi-
cant comorbidity of an unstable or progressive nat-
ure that could interfere with the objectives of this
study. The study was approved by an Institutional
Review Board at each investigational site, and writ-
ten, informed consent was obtained from each
patient.
Study objectives and endpoint measures
The primary objective of the study was to evaluate
the tolerability of lamotrigine when added to cur-
rent AED regimen and as conversion to monother-
apy. Tolerability was assessed by the change in
frequency and severity of adverse events measured
by the Liverpool Adverse Experience Profile (AEP).10
Patients rated each of the 19 items on a 4-point
scale: 1 (never a problem), 2 (rarely a problem), 3
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blem). Clinical consideration of adverse event bur-
den measured with the AEP has been shown to
improve quality of life in patients with epilepsy in
a randomized trial.11 Tolerability was also assessed
by the number of patients reporting serious adverse
events and the number of patients discontinuing the
study due to adverse events related to lamotrigine.
A secondary objective was to evaluate change in
quality of life in patients taking adjunctive and
monotherapy lamotrigine as measured by Quality
of Life in Epilepsy-31 (QOLIE-31). Quality of life is
defined as patients’ perception of their current
level of functioning and satisfaction when compared
to what they perceive to be ideal. The QOLIE-31 is a
subset from Quality of Life in Epilepsy-89, a self-
administered questionnaire designed to specifically
assess quality of life in patients with epilepsy across
nine domains: seizure worry, overall quality of life,
emotional well being, energy/fatigue, cognitive
functioning, medication effects, social functioning,
health status, and an overall score.12 The reliability
and validity of QOLIE-31 have been established.13
An investigator global assessment and patients’
self-rated satisfaction with their treatment were
also assessed. Investigators rated patients’ overall
status on a Likert scale ranging from 1 (marked
deterioration) to 7 (marked improvement) from
baseline to the end of each treatment phase.
Patients rated their satisfaction with their current
epilepsy medication(s) on a Likert scale ranging
from 1 (highly dissatisfied) to 6 (highly satisfied)
from baseline to the end of each phase.
Depressive symptoms may affect quality of life
in patients with epilepsy.14 Therefore, as a supple-
ment to the protocol, the Profile of Mood States
(POMS) was added to assess patients’ mood at
baseline and after the adjunctive and monother-
apy phases. The POMS is a self-rated checklist of 65Figure 1 Stuitems evaluating self-perception of mood with 6
states: fatigue-inertia, vigor-activity, depression-
dejection, anger-hostility, tension-anxiety, and co-
nfusion-bewilderment.15
In addition to the objectives stated above, the
proportion of patients who completed each phase
with at least 50% reduction in seizures from baseline
and proportion of patients who became seizure free
were determined. Because some patients entered
the trial well controlled on their current AED regi-
men, the percent of patients remaining seizure free
throughout each phase was also measured.
Study design
The study (Fig. 1) included a 16-week adjunctive
phase followed by the option to convert to lamo-
trigine monotherapy for an additional 12 weeks for
patients taking a single enzyme-inducing antiepi-
leptic drug (EIAED).
Patients who met the enrollment criteria prior to
initiating study drug completed the AEP, QOLIE-31,
and the patient global rating of satisfaction with
their current epilepsy treatment. Baseline (histor-
ical) seizure frequency was determined retrospec-
tively for the 3 months prior to initiating the study
by patient self-report. For those patients taking
valproate (VPA) or other non-EIAEDs, lamotrigine
was initiated at 25 mg every other day for 2 weeks,
25 mg every day for 2 weeks, and then 25 mg twice
daily for 1 week. Patients taking an EIAED initiated
lamotrigine at 50 mg every day for 2 weeks, 50 mg
twice daily for 2 weeks, and then 100 mg twice daily
for 1 week. Subsequent dose adjustments were
made as clinically indicated to a target maintenance
dose of 100—500 mg per day. During the adjunctive
phase, adjustment to background AEDs was allowed
in keeping with usual clinical practice. Patientsdy design.
Lamotrigine adjunctive and monotherapy 257
Table 1 Baseline demographics.
Number of patients 547
Age 42.7  14.8 years
Range: 16—93 years
Gender 58% female
42% male
Seizure typea Complex partial with
generalization 69%
Complex partial without
generalization 58%
Simple partial 19%
Generalized tonic
clonic 19%
Mean seizures/month 7.6  24.2
Median seizures/month 2
Seizure-free at baseline 14%
Baseline AEDb Carbamazepine 38%
Phenytoin 35%
Valproic acid 25%
Gabapentin 11%
Phenobarbital 10%
Topiramate 10%
other 10%
a Patients could report more than one seizure type.
b Patients could be taking one or two AEDs at baseline.were asked to complete seizure diaries during the
final 8 weeks of each phase.
Upon completion of 16 weeks of adjunctive ther-
apy, investigators performed the global assessment
and patients completed the AEP, QOLIE-31, and the
rating of satisfaction with their current epilepsy
treatment. At this time, patients on a single EIAED
were given the option to convert to lamotrigine
monotherapy and continue in the study for an addi-
tional 12 weeks if deemed appropriate by the inves-
tigator. Those patients who did not enter the
monotherapy phase were discontinued from the
study and treated according to the investigator’s
usual clinical practice. Background concurrent
EIAED was gradually withdrawn (25% reduction in
daily dose per week) over a period of 4 weeks and
lamotriginemonotherapy was continued for an addi-
tional 8 weeks. At the end of the monotherapy
phase, investigators conducted a global assessment
and patients completed the AEP, QOLIE-31, and the
rating of satisfaction with their current epilepsy
treatment. Investigators also reported all serious
adverse events and reasons leading to premature
discontinuation from the study.
Data analysis
Mean overall change scores from baseline to the end
of adjunctive and monotherapy for the AEP, QOLIE-
31 and POMS were analyzed using paired t-tests. For
all statistical tests, p < 0.05 was considered signif-
icant. Investigator’s global assessment scores,
patient satisfaction with AEDs, and change in sei-
zure frequency were summarized using descriptive
statistics only.Results
Demography
Upon completion of screening, 547 adult patients,
mean age 42.7 years, 58% female, entered the
adjunctive phase of the study at 116 sites across
the United States. Demographic information is sum-
marized in Table 1. Reasons for study entry were
inadequate seizure control (45%), unacceptable side
effects (25%), or both (30%). Fourteen percent of
patients reported no seizures during the historical
baseline period. Before enrollment, only 5% of
patients were highly satisfied with their current
AED treatment.
Of the 547 patients who entered the adjunctive
phase, 77% (n = 421) completed it (Fig. 2). Mean
adjunctive lamotrigine maintenance dose was
201  106 mg/day in patients on concurrent VPAand 300  119 mg/day in patients not on concurrent
VPA.
One hundred and seventy-eight (178) patients
were eligible for and attempted conversion to lamo-
trigine monotherapy. Eighty percent (n = 143) com-
pleted the monotherapy phase (Fig. 2). Mean
monotherapy maintenance lamotrigine dose was
412  115 mg/day.
Tolerability
Mean improvement from baseline in AEP score was
4.3 at end of the adjunctive phase ( p < 0.0001) and
5.9 by the end of monotherapy (p < 0.0001). In
patients discontinuing prematurely, mean improve-
ment in AEP total score from baseline was 3.3
(p = 0.0019).
A total of 32 (6%) patients reported serious
adverse events, including two cases of rash (neither
was Stevens Johnson Syndrome). Sixty-eight
patients discontinued the study because of lamo-
trigine related adverse events, although the specific
event leading to discontinuation was not collected.
Quality of life
Patients who completed the QOLIE-31 at the end of
each phase were included in the analyses (n = 396
adjunctive and n = 130 monotherapy). Results are
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Figure 2 Patient accountability.reported as improvement from baseline to the end
of adjunctive therapy and monotherapy (Fig. 3). All
domains showed improvement and reached statis-
tical significance ( p < 0.0001) versus baseline. A
change of approximately 11 total points or more
on QOLIE-31 scales is considered be clinically sig-
nificant.16 QOLIE-31 domains that showed this
degree of improvement included: seizure worry,
energy/fatigue, cognitive functioning and medica-
tion effects.Figure 3 Quality of Life in Epilepsy (QOLIE-31): In
patients completing each phase, the mean QOLIE-31
change from baseline scores after adjunctive and mono-
therapy were statistically significant across all domains
(p < 0.01).Global assessments
Based on the investigator’s assessment, 71% of
patients improved in global status at the completion
of lamotrigine adjunctive therapy. This increased to
92% of patients completing the monotherapy phase.
During monotherapy, investigators reported that
some patients experienced mild (1%) or moderate
(1%) deterioration in their overall status, and 5%
experienced no change.
In the self-rated global assessment of satisfaction
with AED regimen, 33% of patients reported being
highly satisfied upon completion of lamotrigine
adjunctive therapy compared with 5% at baseline.
At the end of monotherapy, 56% of patients reported
being highly satisfied with lamotrigine treatment.
Mood
In the subset of patients completing the Profile of
Mood States, mean total mood disturbance score
improved from 54 at baseline (n = 198) to 33 at the
end of adjunctive therapy (n = 158), p < 0.001.
Further improvements were noted at the end of
monotherapy (n = 52), to a mean total mood dis-
turbance of 31, p < 0.001. Improvements were
noted across all 6 domains of the POMS.
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All data reported below include only patients who
provided acceptable seizure diaries after complet-
ing each phase (i.e., approximately half of the
patients enrolled). Therefore, improvements in sei-
zure control in the group of patients who were
compliant with study procedures may not be repre-
sentative of the entire study population. After com-
pleting the adjunctive therapy phase, 144 of 206
(70%) experienced at least a 50% reduction in seizure
frequency from baseline and 75 (36%) became sei-
zure free. Of the 28 patients seizure free at base-
line, 25 (89%) remained seizure free. Seven patients
discontinued for lack of efficacy during the adjunc-
tive phase.
Among the patients that completed the mono-
therapy phase 51 of 63 (81%) experienced at least a
50% reduction in partial seizure frequency from
baseline and 31 (49%) became seizure free. Of the
18 patients seizure free at baseline 12 (67%)
remained seizure free. Eleven patients discontin-
ued for lack of efficacy during the monotherapy
phase.Discussion
The results of this study suggest that lamotrigine
improved AED regimen tolerability. Patients who
completed the adjunctive and monotherapy phases
also experienced an improvement in quality of life,
satisfaction with drug regimen, and mood during
lamotrigine adjunctive therapy. These parameters
improved even further upon conversion to mono-
therapy.
During adjunctive therapy, patients showed an
improvement in all domains of the AEP. When
patients were converted to monotherapy, tolerabil-
ity improved even further. These results suggest
that the adverse events experienced initially during
adjunctive therapy may have been attributable to
the concurrent baseline AED or related to additive
or pharmacodynamic effects of the AEDs combined.
It has been shown previously that lamotrigine mono-
therapy has a lower incidence of adverse events
than lamotrigine adjunctive therapy.7 Gilliam
recently reported results from a randomized clinical
trial in which use of the AEP was compared with
usual care.11 Patients whose physicians were aware
of AEP score showed greater improvement on AEP
score: 25% versus 5% for usual care, p < 0.01.
Improvement in quality of life was noted in over-
all score on the QOLIE-31. Patients improved most
markedly on the domains of medication effects,
seizure worry and cognitive functioning. While itis known that epilepsy can impair quality of life, it is
also known that epilepsy can adversely affect
patient’s mood. Based on the POMS, patients
reported improvement in total mood disturbance
during both the adjunctive and monotherapy
phases. This observation is consistent with previous
findings that showed lamotrigine improved mood in
patients with complex partial seizures17 and in
patients with epilepsy treated with lamotrigine
monotherapy in a double-blind trial.18
Along with improved tolerability, the majority of
patients completing the study also experienced an
increase in levels of satisfaction with their current
AED therapy. Satisfaction improved over baseline
during lamotrigine adjunctive therapy and improved
further with monotherapy. Improved satisfaction
may result in improved adherence to AED regimens
resulting in better clinical effectiveness. Investiga-
tors reported a significant improvement in the
majority of patients during adjunctive therapy
and a significant improvement in almost all patients
once converted to monotherapy.
This study has several limitations. First, the open-
label design makes it difficult to associate any
improvements with the drug under study. Patient
adherence with study procedures was not optimal,
as indicated by the number of patients that did not
complete seizure diaries. When patients discontin-
ued the study prematurely for adverse events, the
specific event was not captured, a practice that
makes it impossible to determine the types of events
that led to discontinuation. Finally, analysis of end-
points included only patients who completed each
phase of the study as opposed to a more rigorous
intent-to-treat approach.
The importance of these data lies in the fact
that large, community-based studies can provide
tolerability and effectiveness information that add
to or amplify data obtained from pre-approval,
double-blind clinical trials. Differing clinical prac-
tice settings and practitioner approaches to treat-
ment of epilepsy make generalizability of safety
and efficacy from rigorous, well-controlled, clin-
ical trials difficult. Despite the shortcomings of the
open-label design, the results of this study are
consistent with those reported in controlled clin-
ical trials. Therefore, this study supports the utility
of lamotrigine adjunctive therapy and monother-
apy in patients requiring a change in their AED
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